title: Azacitidine in a patient with myelodysplastic syndrome: Impact of switching from a 5-day to the approved 7-day dosing schedule.
authors: M T
authors: MT
authors: Voso
authors: L
authors: L
authors: Fianchi
authors: M
authors: M
authors: Criscuolo
authors: M
authors: M
authors: Greco
authors: F
authors: F
authors: D'Alo
authors: S
authors: S
authors: Hohaus
authors: L
authors: L
authors: Pagano
authors: G
authors: G
authors: Leone
mesh_terms: D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D001374:Azacitidine / Q000008:administration & dosage*; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D017277:Drug Approval; D006801:Humans; D008297:Male; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D013997:Time Factors
chemical_list: D000964:Antimetabolites, Antineoplastic; D001374:Azacitidine